GSK: Depemokimab And Jemperli Lead Next Wave (Rating Upgrade)

By the way, GSK, realizing its potential in the MSI-H/dMMR market, is actively developing it for the treatment of colon ...
Fierce Pharma

GSK’s long-acting asthma med scores in suite of CHMP drug endorsements

GSK’s depemokimab, a long-acting biologic that’s key in the British pharma’s growth plan, has won an endorsement from ...
TipRanks on MSN

GSK announced the CHMP of EMA recommended approval of depemokimab

GSK (GSK) announced that the Committee for Medicinal Products for Human Use, CHMP, of the European Medicines Agency, EMA, has recommended the ...
TipRanks on MSN

GSK’s depemokimab receives positive EMA opinion for severe asthma and CRSwNP

GlaxoSmithKline ( ($GB:GSK) ) has shared an update. GSK has announced that the European Medicines Agency’s Committee for Medicinal Products for ...

GSK Stock Up Almost 19% in 3 Months: Should You Buy, Hold or Sell?

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.
Medical Dialogues

Biologics Show Big Promise in Restoring Sense of Smell in CRSwNP, Meta-Analysis Finds

Denmark: A new systematic review and meta-analysis has shed light on how effectively biologic therapies can help restore the ...
Medindia

Celltrion announces U.S. FDA approval of 300mg strength of OMLYCLO® (omalizumab-igec), the first and only FDA-approved interchangeable biosimilar to XOLAIR®

U.S. Food and Drug Administration (FDA) has approved a new presentation of OMLYCLO® (omalizumab-igec), the first and only biosimilar designated as interchangeable with XOLAIR® (omalizumab), in a 300mg ...

Upstream Bio Reports Third Quarter 2025 Financial Results and Highlights Continued Progress

Detailed price information for Upstream Bio Inc (UPB-Q) from The Globe and Mail including charting and trades.